EPRX Stock Chart & Stats
$5.81
$0.31(5.34%)
At close: 4:00 PM EDT
$5.81
$0.31(5.34%)
Day’s Range― - ―
52-Week Range$5.04 - $9.32
Previous CloseN/A
Volume182.59K
Average Volume (3M)148.90K
Market Cap
$445.95M
Enterprise Value$469.12
Total Cash (Recent Filing)$138.98M
Total Debt (Recent Filing)$2.01M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding65,906,630
10 Day Avg. Volume43,828
30 Day Avg. Volume148,898
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside192.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-delivery PlatformEupraxia’s DiffuSphere platform is a durable competitive asset: it enables targeted, extended-release corticosteroid delivery that can reduce systemic exposure and be applied across multiple inflammatory indications. Platform-based franchises and licensing can compound value beyond any single asset.
Low Leverage And Stronger Balance SheetThe company’s materially reduced leverage and sizable equity/assets provide resilience against clinical-stage funding shocks, extending runway and lowering near-term insolvency risk. This recapitalization since 2023 improves optionality for executing trials or seeking partnerships without immediate forced distress financing.
Cash Losses Align With Cash FlowReported losses largely reflect actual cash outflows rather than accounting non-cash items, making cash runway and financing needs more predictable. That transparency reduces model risk for investors and suggests operating spend is driving losses rather than volatile accounting charges.
Bears Say
Pre-revenue OperationsEupraxia remains fully pre-revenue, meaning no commercial validation or product cash inflows. Long timelines to approval and commercial launch create binary outcomes where product success or failure materially alters prospects, keeping financing dependence and execution risk elevated for months to years.
Significant And Accelerating Cash BurnSustained negative operating and free cash flow, and acceleration versus prior periods, heighten the probability of near-term outside financing. That creates dilution risk, constrains strategic flexibility, and forces management to prioritize funding milestones over optional longer-term investments.
Widening Net LossesIncreasing net losses reflect rising R&D and operating spend ahead of commercialization. Persistent negative returns and deeper losses strain long-term shareholder value unless clinical progress converts into approvals or lucrative partnerships that offset recurring funding needs.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $5.04 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is $445.95M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 87 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported -$0.221 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.003.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,906,630 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.221 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went down -3.284%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (192.60% Upside)
$17.00 (192.60% Upside)
Blogger Sentiment
Bullish
EPRX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
516.50%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(192.60% Upside)
Technical Analysis
Ownership Overview
10.55% Insiders
0.03% Mutual Funds
25.21% Other Institutional Investors
64.05% Public Companies and
Individual Investors